Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy
Abstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-EGFR mAbs has become an important factor restricti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-022-00960-x |
| _version_ | 1811264885745516544 |
|---|---|
| author | Shanshan Wei Wenwei Hu Jun Feng Yiting Geng |
| author_facet | Shanshan Wei Wenwei Hu Jun Feng Yiting Geng |
| author_sort | Shanshan Wei |
| collection | DOAJ |
| description | Abstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-EGFR mAbs has become an important factor restricting its efficacy. Recent studies have revealed that non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are implicated in anti-EGFR antibodies resistance, affecting the sensitivity of CRC cells to Cetuximab and Panitumumab. This paper briefly reviewed the research advance of the expression, signaling network and functional mechanism of ncRNAs related to anti-EGFR mAbs resistance in CRC, as well as their relationship with clinical prognosis and the possibility of therapeutic targets. In addition, some ncRNAs that are involved in the regulation of signaling pathways or genes related to anti-EGFR resistance, but need to be further verified by resistance experiments were also included in this review, thereby providing more ideas and basis for ncRNAs as CRC prognostic markers and anti-EGFR therapy sensitizers. Video Abstract |
| first_indexed | 2024-04-12T20:12:24Z |
| format | Article |
| id | doaj.art-3a1139c3183b4809bcd6acc28ae04267 |
| institution | Directory Open Access Journal |
| issn | 1478-811X |
| language | English |
| last_indexed | 2024-04-12T20:12:24Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj.art-3a1139c3183b4809bcd6acc28ae042672022-12-22T03:18:12ZengBMCCell Communication and Signaling1478-811X2022-09-0120111910.1186/s12964-022-00960-xPromotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapyShanshan Wei0Wenwei Hu1Jun Feng2Yiting Geng3Department of Oncology, The Third Affiliated Hospital of Soochow UniversityDepartment of Oncology, The Third Affiliated Hospital of Soochow UniversityDepartment of Oncology, The Third Affiliated Hospital of Soochow UniversityDepartment of Oncology, The Third Affiliated Hospital of Soochow UniversityAbstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-EGFR mAbs has become an important factor restricting its efficacy. Recent studies have revealed that non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are implicated in anti-EGFR antibodies resistance, affecting the sensitivity of CRC cells to Cetuximab and Panitumumab. This paper briefly reviewed the research advance of the expression, signaling network and functional mechanism of ncRNAs related to anti-EGFR mAbs resistance in CRC, as well as their relationship with clinical prognosis and the possibility of therapeutic targets. In addition, some ncRNAs that are involved in the regulation of signaling pathways or genes related to anti-EGFR resistance, but need to be further verified by resistance experiments were also included in this review, thereby providing more ideas and basis for ncRNAs as CRC prognostic markers and anti-EGFR therapy sensitizers. Video Abstracthttps://doi.org/10.1186/s12964-022-00960-xAnti-EGFR monoclonal antibodyColorectal cancerResistancencRNAlncRNAmiRNA |
| spellingShingle | Shanshan Wei Wenwei Hu Jun Feng Yiting Geng Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy Cell Communication and Signaling Anti-EGFR monoclonal antibody Colorectal cancer Resistance ncRNA lncRNA miRNA |
| title | Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy |
| title_full | Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy |
| title_fullStr | Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy |
| title_full_unstemmed | Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy |
| title_short | Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy |
| title_sort | promotion or remission a role of noncoding rnas in colorectal cancer resistance to anti egfr therapy |
| topic | Anti-EGFR monoclonal antibody Colorectal cancer Resistance ncRNA lncRNA miRNA |
| url | https://doi.org/10.1186/s12964-022-00960-x |
| work_keys_str_mv | AT shanshanwei promotionorremissionaroleofnoncodingrnasincolorectalcancerresistancetoantiegfrtherapy AT wenweihu promotionorremissionaroleofnoncodingrnasincolorectalcancerresistancetoantiegfrtherapy AT junfeng promotionorremissionaroleofnoncodingrnasincolorectalcancerresistancetoantiegfrtherapy AT yitinggeng promotionorremissionaroleofnoncodingrnasincolorectalcancerresistancetoantiegfrtherapy |